MarketPulse

first-in-class

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Ipsen Unveils Early-Stage Immuno-Oncology Breakthroughs at AACR Congress

Ipsen presents preclinical data for two first-in-class cancer candidates targeting solid tumors and gastrointestinal cancers, advancing its immuno-oncology pipeline.
IPSEYantibody-drug conjugatesolid tumors
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Atea's AT-587 Shows Promise as Potential First HEV Treatment in Preclinical Study

Atea's AT-587 shows promise as first potential HEV treatment, demonstrating 30-150x greater antiviral activity than existing agents in preclinical studies. Phase 1 trials expected mid-2026.
AVIRPhase 1 clinical trialHepatitis E Virus